Pharmaceuticals for the treatment of serious and life-threatening diseases, namely, lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis

'cystic':25 'diseas':11 'due':23 'exocrin':20 'fibrosi':26 'glomerulonephr':16 'iga':17 'insuffici':22 'life':9 'life-threaten':8 'lupus':13,14 'name':12 'nephropathi':18 'pancreat':21 'pharmaceut':1 'serious':6 'threaten':10 'treatment':4

Developing clinical pharmaceutical products; research and development in the pharmaceutical and biotechnology fields

'biotechnolog':12 'clinic':2 'develop':1,7 'field':13 'pharmaceut':3,10 'product':4 'research':5

Licensing late-stage clinical pharmaceutical products, namely, pharmaceuticals for the treatment of lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis

'clinic':5 'cystic':26 'due':24 'exocrin':21 'fibrosi':27 'glomerulonephr':17 'iga':18 'insuffici':23 'late':3 'late-stag':2 'licens':1 'lupus':14,15 'name':8 'nephropathi':19 'pancreat':22 'pharmaceut':6,9 'product':7 'stage':4 'treatment':12

ANTHERA

Owners

Goods & Services